Trial Profile
A comparative study of 24-hour and 6-hour Infusion of Nafamostat Mesilate for Prevention of Post-ERCP Pancreatitis: a Prospective Randomized Comparison Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Nafamostat (Primary)
- Indications Pancreatitis
- Focus Therapeutic Use
- 07 Sep 2016 New trial record